A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Aβ) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Salloway, S, Sperling, R, Gilman, S, Fox, N C., Blennow, K, Raskind, M, Sabbagh, M, Honig, L S., Doody, R, van Dyck, C H., Mulnard, R, Barakos, J, Gregg, K M., Liu, E, Lieberburg, I, Schenk, D, Black, R, Grundman, M
Formato: Artigo
Lenguaje:Inglês
Publicado: American Academy of Neurology 2009
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2790221/
https://ncbi.nlm.nih.gov/pubmed/19923550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181c67808
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares